Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q08379
UPID:
GOGA2_HUMAN
Alternative names:
130 kDa cis-Golgi matrix protein; GM130 autoantigen; Golgin-95
Alternative UPACC:
Q08379; A0A0C4DGS5; Q6GRM9; Q9BRB0; Q9NYF9
Background:
Golgin subfamily A member 2, also known as GM130, is a pivotal peripheral membrane component of the cis-Golgi stack. It plays a crucial role in maintaining the Golgi apparatus's structure, facilitating vesicle fusion, and ensuring normal protein transport from the endoplasmic reticulum. GM130 is instrumental in mitotic Golgi disassembly, spindle pole assembly, and centrosome organization, highlighting its central role in cell division and structural integrity.
Therapeutic significance:
The association of GM130 with developmental delay, hypotonia, myopathy, and brain abnormalities underscores its potential as a therapeutic target. Understanding GM130's role could open doors to novel strategies for treating these neurodevelopmental disorders.